Sero-epidemiological evaluation of malaria transmission in The Gambia before and after mass

drug administration

Author details

Lindsey Wu[1], Julia Mwesigwa[2], Muna Affara[3], Mamadou Bah[2], Simon Correa[2], Tom Hall[4], James

Beeson[5], Kevin K.A. Tetteh[1], Immo Kleinschmidt[6,7], Umberto D'Alessandro[2], Chris Drakeley[1]

1. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Infectious Tropical

Diseases, Department of Infection Biology. London WC1E 7HT, UK.

2. Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine.

Fajara, The Gambia.

3. Bernhard Nocht Institute for Tropical Medicine (BNITM). Arusha, Tanzania.

4. St. George's University of London (SGUL). SW17 0RE, London, United Kingdom.

5. Burnet Institute. Melbourne, Victoria, 3004, Australia.

6. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Epidemiology and

Population Health, Department of Infectious Disease Epidemiology. London WC1E 7HT, UK.

7. School of Pathology, Wits Institute for Malaria Research, Faculty of Health Science, University of

Witwatersrand. Johannesburg, South Africa.

Email addresses:

LW: lindsey.wu@lshtm.ac.uk

JM: julia.mwesigwa@lshtm.ac.uk

MA: affara@bnitm.de

MB: mmbah@mrc.gm

SC: scorrea@mrc.gm

TH: thall@sgul.ac.uk

JB: beeson@burnet.edu.au

KKAT: kevin.tetteh@lshtm.ac.uk

IK: immo.kleinschmidt@lshtm.ac.uk

UD: umberto.dalessandro@lshtm.ac.uk

CD: chris.drakeley@lshtm.ac.uk

Keywords: malaria, serology, mass drug administration, surveillance

Abstract: 200

Word count: 3,425

Abstract

Background

As The Gambia aims to achieve elimination by 2030, serological assays can be a useful surveillance

tool to monitor trends in malaria incidence and evaluate community-based interventions.

Methods

Spatio-temporal variation in transmission in four Gambian study villages was measured using a panel

of novel recombinant *Pf* antigens on a multiplexed bead-based serological assay. Village-level

antibody levels were quantified as under-15 sero-prevalence, sero-conversion rates, and age-

adjusted antibody acquisition rates. Antibody levels prior to mass drug administration (MDA) were

assessed for their association with persistent malaria infection after community chemoprophylaxis.

Results

Seasonal changes in antibodies to Etramp5.Ag1 were observed in children under 15 in two

transmission settings. At the end of the malaria season, short-lived antibody responses to

Etramp5.Ag1, GEXP18, HSP40.Ag1, EBA175, and Rh2.2030 were higher amongst 1-15 year olds in the

Upper River compared to the West Coast Region. Prior to MDA, individuals in the upper 50th

percentile of above-average antibody levels in the dry season had two-fold higher odds of post-MDA

clinical malaria during the transmission season.

Conclusions

Serological markers can serve dual functions as indicators of malaria exposure and incidence.

Further studies, particularly cluster randomised trials, can help establish standardised serological

protocols to measure transmission across endemic settings.

Background

Due to its pronounced seasonality and epidemiological landscape, The Gambia has a long history of research on the heterogeneity of malaria in West Africa. Entomological and clinical data from the late 1980s have shown spatial variation in malaria infections within just two kilometres of mosquito breeding sites that were unexplained by bed-net use and entomological inoculation rates. It was hypothesised that differences in effective immunity between households could be a driving factor in variable patterns of clinical malaria.[1] There have also been landmark studies in The Gambia on community-based interventions, including randomised trials demonstrating the impact on childhood mortality and herd effects from insecticide-treated bed nets[2,3] and additional reductions in clinical malaria when combined with chemoprophylaxis.[4] Subsequently, there have been rapid declines in incidence through the scale-up of control interventions - improved diagnosis and treatment, distribution of long-lasting insecticidal nets (LLINs), indoor residual spraying (IRS), and seasonal malaria chemoprevention (SMC). However, micro-epidemiological variations in transmission remain[5,6], which are increasingly relevant for the evaluation of interventions as The Gambia aims to achieve malaria elimination by 2030.

Previous serological surveys in The Gambia have shown country-wide heterogeneities in malaria transmission, including a 2012 school-based study where strong associations were observed between sero-prevalence and microscopy-detectable parasitaemia.[7] More recent studies have since identified new serological markers of *Plasmodium falciparum (Pf)* malaria exposure that have strong correlations with clinical incidence in Uganda and Mali[8]. These antibody responses are a robust measure of sero-incidence and could supplement existing surveillance tools to monitor transmission and evaluate the effectiveness of community interventions.

In 2013, the Malaria Transmission Dynamics Study assessed epidemiological trends throughout the malaria season (June – December) in six village pairs covering a range of transmission across The Gambia.[5,6] In the following two years, annual rounds of mass drug administration (MDA) with

dihydroartemisnin-piperaquine (DHA-PQ) was also conducted between May and June, targeting

individuals aged 6 months to 75 years in all study villages.[9] Outcomes assessed included incidence of

clinical disease, prevalence of *Pf* infection measured by polymerase chain reaction (PCR), and factors

associated with infection post-MDA.

This study evaluates the use of antibody responses as a measure of malaria exposure and incidence

at the population level. Serological markers of malaria were used to measure spatio-temporal

variation in transmission in a subset of four study villages from the Malaria Transmission Dynamics

Study. A panel of novel recombinant *Pf* antigens were used to quantify population antibody levels

using a multiplexed immuno-assay. Village-level serological profiles were used to describe seasonal

and geographical variation in antibody responses and the association between antibody levels prior

to MDA and persistent malaria infection after community chemoprophylaxis was also estimated.

Methods

Data and sampling

A prospective cohort study was conducted from 2013 to 2015 in six village pairs across five

administrative regions - West Coast (WCR), North Bank (NBR), Lower River (LRR), Central River (CRR)

and Upper River (URR) Regions. *Pf* prevalence measured by PCR ranged from 2.27 to 19.60% in the

Central River and Upper River Regions respectively. As previously described by Mwesigwa et al,[6] the

study aim was to understand the dynamics of malaria infection and the impact of annual MDA.

Residents more than six months of age were enrolled in the study. Monthly surveys were conducted

during malaria transmission season (June to December) each year, in the dry season (April 2014),

and prior to the implementation of MDA (May and June). In both 2014 and 2015, one round of MDA

was conducted, with DHA-PQ administered to individuals aged 6 months and 75 years, according to

weight-based dosing guidelines, over 6 to 14 days between May and June in six pairs of study

villages.

Blood samples were collected by finger prick for haemoglobin measurement, blood smear for

malaria diagnosis by microscopy, and molecular and serological analysis by dried blood spot (DBS) on

filter paper (Whatman 3 Corporation, Florham Park, NJ, USA). Clinical malaria cases were identified

through passive case detection (PCD) at local health facilities or in villages by study nurses; clinical

malaria was defined as history of fever in the previous 24 hours or axillary temperature ≥ 37.5°C and

a positive rapid diagnostic test (RDT) result (Paracheck *Pf*, Orchid Biomedical System, India).

Serological analysis included all available samples from the WCR in Besse and N'Demban from

surveys conducted at the start of the transmission season in July 2013 (N=537) and at the end of the

season in December 2013 (N=526). In the URR, analysis included all samples collected in Njaiyal and

Madino Samako in July 2013 (N=779), December 2013 (N=632), April (dry season) 2014 (N=823), and

December 2014 (N=757). These regions represent extremes of two transmission intensities, with

months selected at the start and end of the transmission season. Samples from clinical PCD cases

were linked by study participant identification code to samples from the same individuals collected

during routine monthly surveys. Samples collected as part of the Malaria Transmission Dynamics

Study and subset of samples for serological analysis are described in Supplementary Figure 1.

Laboratory procedures

A full description of laboratory methods is detailed in Wu et al[10] and Mwesigwa et al[11]. Briefly, serum

samples were eluted from 6mm DBS (4 µL whole blood equivalent) and prepared as a 1:500 dilution.

Two wells on each plate containing only antigen-coupled beads and sample buffer were included to

measure background signal. A pool of 22 serum samples from malaria hyper-immune individuals in

The Gambia were used as positive controls in a 6-point 5-fold serial dilution (1:10 – 1:31,250) and

plasma samples from European malaria-naive adults (1:500 dilution) as negative controls. Serum

samples were processed on the Luminex MAGPIX, with mean fluorescence intensity (MFI) values

between plates normalised according to the protocol described in Wu et al 2019.[12]

For diagnostic PCR, DNA was extracted from three 6-mm DBS (4 μL whole blood equivalent) using

the automated QIAxtractor robot (Qiagen). Negative and positive (3D7) controls were included to

control for cross contamination and DNA extraction efficiency, respectively. Extracted DNA was used

in a nested PCR, amplifying multi-copy *Plasmodium* ribosomal RNA gene sequences using genus and

species-specific primers. All PCR products were run using the QIAxcel capillary electrophoresis

system (Qiagen).

Statistical analyses

Antibody responses were summarised at village level and used to describe geographical differences

in transmission between the West Coast (low transmission) and Upper River Regions (moderate-high

transmission). Temporal changes within each region were assessed using village-level antibody

response during the malaria transmission season (July and December 2013) and in the subsequent

dry season (April 2014). Population antibody responses were represented in several ways as

summarised below.

Sero-prevalence and sero-conversion rate. For antigens associated with longer lived antibody

responses - *P.falciparum* merozoite surface antigen 1 19-kDa carboxy-terminal region (PfMSP1$_{19}$)

and *P.falciparum* apical membrane antigen 1 (PfAMA1), the distribution of MFI for all serological

samples in the study was characterised through a two-component Gaussian mixture model to define

distributions of negative and positive antibody levels. The sero-positivity threshold was defined as

the mean log MFI values plus two standards deviations of the negative distribution.[13] Mixture

models were estimated using the *'normalmixEM'* function in the *'mixtools'* package v1.0.4 in R

version 3.6.1. For antigens associated with shorter-lived antibodies where statistical evidence of a

bimodal distribution of antibody responses in the population is not strong – early transcribed

membrane protein 5 (Etramp5.Ag1), gametocyte export protein 18 (GEXP18), heat shock protein 40

(HSP40.Ag1), erythrocyte binding antigen 175 RIII-V (EBA175), reticulocyte binding protein

homologue 2 (Rh2.2030) - the sero-positivity threshold was defined by the mean log MFI plus three

standard deviations of 71 malaria-naïve European blood donors used as negative controls.

Age-adjusted sero-conversion rates (SCRs), the rate at which sero-negative individuals become sero-

positive per year, were estimated for antigens associated with long-lived antibody response

(PfMSP1$_{19}$, PfAMA1). A reversible catalytic model was fitted to age-adjusted sero-positivity data

using maximum likelihood methods.[14] A common sero-reversion rate for each antigen was assumed

across all villages, which was estimated based on fitting a single sero-catalytic model to all

individuals in the sample and fixing the sero-reversion rate to this value in all subsequent village-

specific model fits. Models were fit for each antigen, and SCRs estimated separately for each village

and survey month.

In addition to sero-conversion rates based on all ages, sero-prevalence for all antigens was

estimated specifically for children aged 1-15 years. Individuals in this age range are less likely to have

high levels of long-lived antibodies from previous malaria exposure and antibodies are more likely to

reflect recent infection. Sero-prevalence based on this age group may also have relevance for

school-based surveys and interventions.[7,15]

Age-dependent antibody acquisition. Antibody acquisition models[16,17] were used to estimate age-

dependent changes in antibody levels. Geometric mean MFI values were calculated for defined age

groups and used to estimate antibody acquisition rates for each antigen, by village, and by monthly

survey. Two variants of the model were used – one assuming that geometric mean antibody levels

increase at a constant rate with age and the second assuming that different antibody acquisition

rates for two distinct age groups (described further in the Supplementary Methods). Area Under the

Antibody Acquisition Curve (AUC) values were calculated based on the model fit for each village and

survey month, representing the cumulative antibody intensity across all ages in the population at

that time.[18] Antibody levels were compared between seasons within regions (URR and WCR) and

between regions for the same season. Strength of evidence for observed differences are presented

as p-values, derived by comparing the posterior distributions of predicted antibody levels over a

specified age range (i.e., all-ages or 1-15 years).

Dry season antibody levels and odds of infection post-MDA. Individual antibody levels in the dry

season (April) prior to the implementation of MDA were assessed by comparing observed and

expected MFI value as predicted by the age-adjusted antibody acquisition model fit for all individuals

in URR-South in April 2014. For individuals with above average MFI values for their age group, the

difference between observed and expected logMFI was calculated and classified to either below or

above median of residual MFI antibody response. Logistic regression was used to estimate the odds

of clinical malaria (passively detected via the health facility or study nurses in the community) or

asymptomatic *Pf* infection (actively detected using PCR from monthly survey samples) during the

transmission season following MDA (October – December 2014) amongst individuals below and

above median residual dry season antibody levels, compared to individuals at or below expected

antibody responses, allowing for clustering at the household/compound. Multivariate analyses also

adjusted for age, LLIN use, and MDA adherence using generalised linear mixed-effects models with

the 'glm' and 'glmer' functions in the 'lme4' v1.1-21 package in R version 3.6.1.

Results

Sero-prevalence in children by geographical region and transmission season. Variation in sero-

prevalence between geographical region and transmission season differed by antigen. More

specifically, differences in sero-prevalence to Etramp5.Ag1 and GEXP18 were observed between July

(start of the transmission season) and December (end of the transmission season) in children aged 1-

15 years in the West Coast Region (Table 1, Supplementary Figure 1). In the URR, there was

statistically strong evidence for differences between July and December for nearly all antigens, with

moderate statistical evidence for GEXP18. No significant decline in sero-prevalence was observed

between December 2013 and April 2014 for any antigen in either region.

Sero-conversion rate between geographical regions and transmission seasons. Differences in SCR

between geographical region and transmission season also varied by antigen (Figures 1 and 2,

Supplementary Table 1). In the West Coast Region, changes in antibody responses between

transmission seasons were larger for PfMSP1$_{19}$ (0.0147 increase in SCR between July and December)

compared to PfAMA1 (0.0007 increase in SCR). In the Upper River Region, seasonal differences

between July and December 2013 for both antigens were larger than the West Coast Region, with an

increase in PfMSP1$_{19}$ SCR of 0.0405 and increase of 0.0301 in PfAMA1 SCR. There was no significant

change in SCR between December 2013 and April 2014 for either antigen.

At the start of the malaria transmission season (July 2013), PfMSP1$_{19}$ SCR was twice as high in the

Upper River Region (SCR 0.0130, 95%CI 0.0088 – 0.0194) compared to the West Coast Region (SCR

0.0067, 95%CI 0.0037 – 0.0123). After peak transmission season, this difference was more

pronounced, with PfMSP1$_{19}$ SCR 0.0214 (95%CI 0.0087 – 0.0530) in the West Coast Region compared

to SCR 0.0535 (95%CI 0.0344 – 0.0831) in the Upper River Region. PfAMA1 SCR in the Upper River

Region was consistently higher than the West Coast Region throughout the transmission season,

with SCR 0.0159 (95%CI 0.0080 – 0.0239) and 0.0614 (95%CI 0.0509 – 0.0740) for the West Coast

and Upper River Regions, respectively, in July, and SCR 0.0166 (95%CI 0.0124 – 0.0224) and 0.0915

(95%CI 0.0738 – 0.1135) in the West Coast and Upper River Regions, respectively, in December.

Increases in sero-prevalence in older age groups are not pronounced for markers associated with

short-lived antibody responses, which is an underlying assumption when using sero-catalytic models.

Therefore, antibody acquisition models are used to assess age-adjusted changes in antibody

responses based on continuous data for markers of short-lived antibody responses.

Age-adjusted antibody acquisition by geographical region and transmission season. For antigens

associated with long-lived antibody responses (PfMSP1$_{19}$ and PfAMA1), differences in age-adjusted

antibody acquisition were observed between the West Coast and Upper River Regions at the end of

the transmission season (December 2013) (Supplementary Figures 5 and 6, Supplementary Tables

S7-S8). For PfMSP1$_{19}$, differences in geometric mean antibody levels in children aged 1-15 years in

the Upper River Region were higher at the end of the transmission season compared to the start of

the season (p=0.025). Additionally, higher antibody levels to PfAMA1 in 1-15 year olds were

observed in the Upper River Region compared to the West Coast Region at the end of the

transmission season (p<0.001). No significant differences in antibody levels for PfAMA1 were

observed between the start and end of transmission season in the Upper River Region.

In contrast to PfMSP1$_{19}$ and PfAMA1, all serological markers associated with shorter-lived antibody

responses (Etramp5.Ag1, GEXP18, HSP.Ag1, EBA175, and Rh2.2030) showed higher antibody levels in

1-15 year olds in the Upper River Region compared to the West Coast Region at the end of the

transmission season (Figures 3-5, Supplementary Figures 3 and 4, Supplementary Tables 2-6). In the

Upper River Region, there were higher antibody responses to Etramp5.Ag1 at the end of the

transmission season amongst individuals aged 1-15 years (p=0.001). However, antibody levels in 1-

15 year olds for HSP40.Ag1 were lower at the end of the transmission season in the West Coast

Region (p=0.004). At the start of the transmission season, antibody levels to GEXP18 were higher in

the Upper River compared to the West Coast Region (p=0.032). There were no within-region

differences in antibody responses between the dry season (April 2014) and the transmission season

(December 2013 and 2014) for any of the antigens tested.

Association between pre-MDA antibody levels and post-MDA malaria infection.

After adjusting for age, LLIN use in the last 24 hours, and MDA compliancy, individuals in the upper

50th percentile of above-average antibody levels to Etramp5.Ag1 for their age group in the dry

season (April 2014, before the implementation of MDA) had two-fold higher odds of clinical malaria

(aOR 1.91 95%CI 1.053– 3.52, p=0.039) in the transmission season (October – December 2014) after

MDA (Figure 6A, Supplementary Table 9). Dry season antibody levels to Rh2.2030 were also

moderately associated with increased odds of clinical malaria (OR 1.75 95%CI 0.93 – 3.30, p=0.085)

after MDA (Figure 6A, Supplementary Table 13), but statistical evidence was not strong. Similarly,

there was a borderline association between above average antibody levels to *Pf*AMA1 in the dry

season and increased odds of clinical malaria (OR 1.70 95%CI 0.97 – 2.98, p=0.065) but statistical

association was weak after adjusting for age, LLIN use and MDA compliancy (Figures 6A,

Supplementary Table 15). Antibody responses to all other antigens investigated were not associated

with increased odds of infection post-MDA (Supplementary Tables 10-14).

Discussion

This study investigated a range of indicators characterising population-level antibody responses.

Spatio-temporal variations in serological responses were observed for several *P.falciparum* antigens.

There were seasonal differences in sero-prevalence for nearly all antigens in the higher transmission

setting (Upper River Region) as well as in the low transmission West Coast Region (Etramp5.Ag1 and

GEXP18) amongst children aged 1-15 years. These differences likely reflect a combination of changes

in malaria incidence as well residual antibodies from prior infection. In moderate to high

transmission settings, higher antibody levels amongst older children in the dry season is common,

where immunity to clinical malaria is acquired after 10 to 15 years of exposure.[19,20] Children in this

age range may be a useful sentinel population to monitor transmission in school-based surveys. This

could also be used to evaluate the effectiveness of malaria control interventions or identify areas at

risk of increased clinical incidence. It is important to note that nearly all malaria indicators or survey

designs are associated with a degree of bias that may result in underestimation of transmission. For

example, school surveys may be less appropriate in South East Asia where the age distribution of

malaria differs to sub-Saharan Africa. Serological surveillance protocols should therefore be

designed to align or be combined with other routine measures of transmission.

Differences in sero-conversion rates to *Pf*MSP1$_{19}$ and *Pf*AMA1 were observed between geographical

regions but not between transmission seasons in the same region. Long-lived antibody responses

likely reflect past malaria exposure rather than short-term changes in sero-incidence within a single

transmission season and statistical methods to confirm differences in sero-conversion rates still

require harmonisation between researchers. However, these markers have been shown to be

sensitive to changes in transmission over longer periods of time in The Gambia.[21] Antibody

acquisition models can detect more subtle differences in the magnitude of antibody levels,

particularly for antigens associated with short-lived antibody responses. All five of the novel sero-

incidence markers evaluated in this study - Etramp5.Ag1, GEXP18, HSP40.Ag1, EBA175, and

Rh2.2030 - detected geographical differences in antibody acquisition. Additionally, a subset of these

markers (Etramp5.Ag1 and HSP40.Ag1) were also able to detect seasonal differences in high and low

transmission settings.

Between December 2013 and April 2014, antibody levels did not decline significantly for any

antigens except GEXP18, indicating that antibody decay at the population level likely occurs over a

period longer than four months. This may be due to persistent parasitaemia in asymptomatic

individuals or infections occurring late in the transmission season in December. While findings are

based on limited timepoints, several longitudinal studies in The Gambia have observed measurable

antibody decay in children in the dry season against antigens associated with protective

immunity.[22,23] Similar studies in Mali have quantified antibody responses to over 2,000 *P.falciparum*

antigens on protein microarray before and after the malaria season and observed rapid declines in

children under 10 within six months of the end of the transmission season.[24] Further research to

estimate the longevity of antibody responses across all ages could help determine optimal sampling

timeframes (and populations) for future serological surveillance.

Above average antibody levels in the dry season before MDA were associated with increased odds of

clinical malaria following MDA. Associations were moderate for Rh2.2030 and *Pf*AMA1, but

individuals with higher than average antibody levels against Etramp5.Ag1 had a two-fold higher odds

of clinical malaria post-MDA. Similar associations were also observed with parasitological endpoints,

as previously reported by Mwesigwa et al, where individuals with *P.falciparum* infection (detected

by PCR) in the dry season had increased odds of re-infection during the post-MDA transmission

season.[9] This study was not designed to assess the effectiveness of MDA using serological endpoints,

so sample size may not be adequately powered to draw strong conclusions. However, it is possible

that assessing serological responses in different months, where sampling frequency is informed by

antibody boost and decay rates, could provide more accurate information. Analysis of a larger set of

antigens or grouping antibody data based on antigen expression or function during the parasite life

cycle may help delineate the wide range of responses with respect to malaria exposure, incidence,

or immunity. Studies measuring persistent asymptomatic parasitaemia throughout the dry and wet

seasons would also further elucidate the dynamics between parasite density, immunity, and

serological response.

This study has demonstrated that a large number of new serological markers of malaria can be

optimised for high throughput use on an affordable immuno-assay platform. Findings also show the

duality of using a diverse serological panel of markers to monitor malaria exposure (observed

through long-lived antibody responses) and malaria incidence (observed through shorter-lived

antibody responses). Extension of this research to larger studies, particularly cluster randomised

trials, can help to establish standardised serological protocols for measuring transmission for use

across a variety of epidemiological settings.

List of abbreviations

aOR: Adjusted odds ratio

AUC: Area Under the Antibody Acquisition Curve

CI: Confidence interval

DBS: Dried blood spot

DHA-PQ: Dihydroartemisnin-piperaquine

EBA175: Erythrocyte binding antigen 175 RIII-V

Etramp5.Ag1: Early transcribed membrane protein 5

GEE: Generalised estimating equations

GEXP18: Gametocyte export protein 18 (GEXP18)

HSP40.Ag1: Heat shock protein 40

IgG: Immunoglobulin

LLIN: Long-lasting insecticide treated net

MDA: Mass drug administration (MDA)

MFI: Median fluorescence intensity

PCD: Passive case detection

PCR: Polymerase chain reaction

Pf, P.falciparum: *Plasmodium falciparum*

*Pf*AMA1: *P.falciparum* apical membrane antigen 1

*Pf*MSP1$_{19}$: *P.falciparum* merozoite surface antigen 1 19-kDa carboxy-terminal region

RDT: Rapid diagnostic test

Rh2.2030: Reticulocyte binding protein homologue 2

SCR: Sero-conversion rate

URR: Upper River Region, The Gambia

WCR: West Coast Region, The Gambia

Ethics approval and consent to participate

This study was approved by the Gambia Government/MRC Joint Ethics Committee (SCC1318). Verbal

consent was first obtained at village sensitisation meetings, followed by individual written informed

consent for all participants. Parents/guardians provided written consent for children less than

17 years, and assent was obtained from children between 12 and 17 years.

Competing interests

All authors declare no competing interests.

Funding

This work was supported by the UK Medical Research Council (UKMRC) through the LSHTM Doctoral

Training Programme studentship received by LW. The funders had no role in the design of the study,

collection, analysis, interpretation of data or writing of the manuscript.

Corresponding author

Lindsey Wu

London School of Hygiene and Tropical Medicine

Faculty of Infectious and Tropical Diseases

Department of Infection Biology

Keppel Street

London

WC1E 7HT

+44 (0) 797 243 5577

lindsey.wu@lshtm.ac.uk

References

1.   Thomas, C. J. & Lindsay, S. W. Local-scale variation in malaria infection amongst rural

371   Gambian children estimated by satellite remote sensing. *Trans. R. Soc. Trop. Med. Hyg.* **94**,

372   159–63

373   2.   D'Alessandro, U. *et al.* Mortality and morbidity from malaria in Gambian children after

374   introduction of an impregnated bednet programme. *Lancet* **345**, 479–483 (1995).

375   3.   Snow, R. W., Rowan, K. M., Lindsay, S. W. & Greenwood, B. M. A trial of bed nets (mosquito

376   nets) as a malaria control strategy in a rural area of The Gambia, West Africa. *Trans. R. Soc.*

377   *Trop. Med. Hyg.* **82**, 212–5 (1988).

378   4.   Alonso, P. L. *et al.* A malaria control trial using insecticide-treated bed nets and targeted

379   chemoprophylaxis in a rural area of The Gambia, West Africa: 6. The impact of the

380   interventions on mortality and morbidity from malaria. *Trans. R. Soc. Trop. Med. Hyg.* **87**, 37–

381   44 (1993).

382   5.   Mwesigwa, J. *et al.* On-going malaria transmission in The Gambia despite high coverage of

383   control interventions: a nationwide cross-sectional survey. *Malar. J.* **14**, 314 (2015).

384   6.   Mwesigwa, J. *et al.* Residual malaria transmission dynamics varies across The Gambia despite

385   high coverage of control interventions. *PLoS One* **12**, e0187059 (2017).

386   7.   Okebe, J. *et al.* School-Based Countrywide Seroprevalence Survey Reveals Spatial

387   Heterogeneity in Malaria Transmission in the Gambia. *PLoS One* **9**, e110926 (2014).

388   8.   Helb, D. A. *et al.* Novel serologic biomarkers provide accurate estimates of recent

389   Plasmodium falciparum exposure for individuals and communities. *Proc. Natl. Acad. Sci. U. S.*

390   *A.* **112**, E4438-47 (2015).

391   9.   Mwesigwa, J. *et al.* Mass Drug Administration With Dihydroartemisinin-piperaquine and

392   Malaria Transmission Dynamics in The Gambia: A Prospective Cohort Study. *Clin. Infect. Dis.*

393   **69**, 278–286 (2019).

10.   Wu, L. *et al.* Optimisation and standardisation of a multiplex immunoassay of diverse

Plasmodium falciparum antigens to assess changes in malaria transmission using sero-

epidemiology. *Wellcome Open Res.* **4**, 26 (2019).

11.   Snounou, G. Genotyping of Plasmodium spp. Nested PCR. *Methods Mol. Med.* **72**, 103–116

(2002).

12.   Wu, L. *et al.* Optimisation and standardisation of a multiplex immunoassay of diverse

Plasmodium falciparum antigens to assess changes in malaria transmission using sero-

epidemiology. *Wellcome Open Res.* **4**, 26 (2019).

13.   Stewart, L. *et al.* Rapid assessment of malaria transmission using age-specific sero-conversion

rates. *PLoS One* **4**, e6083 (2009).

14.   Drakeley, C. J. *et al.* Estimating medium- and long-term trends in malaria transmission by

using serological markers of malaria exposure. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 5108–13

(2005).

15.   Stevenson, J. C. *et al.* Reliability of School Surveys in Estimating Geographic Variation in

Malaria Transmission in the Western Kenyan Highlands. *PLoS One* **8**, e77641 (2013).

16.   Weber, G. E. *et al.* Sero-catalytic and Antibody Acquisition Models to Estimate Differing

Malaria Transmission Intensities in Western Kenya. *Sci. Rep.* **7**, (2017).

17.   Yman, V. *et al.* Antibody acquisition models: A new tool for serological surveillance of malaria

transmission intensity. *Sci. Rep.* **6**, 19472 (2016).

18.   Arnold, B. F. *et al.* Measuring changes in transmission of neglected tropical diseases, malaria,

and enteric pathogens from quantitative antibody levels. *PLoS Negl. Trop. Dis.* **11**, e0005616

(2017).

19.   Carneiro, I. *et al.* Age-Patterns of Malaria Vary with Severity, Transmission Intensity and

Seasonality in Sub-Saharan Africa: A Systematic Review and Pooled Analysis. *PLoS One* **5**,

e8988 (2010).

20.   Griffin, J. T., Ferguson, N. M. & Ghani, A. C. Estimates of the changing age-burden of

Plasmodium falciparum malaria disease in sub-Saharan Africa. *Nat. Commun.* **5**, 3136 (2014).

21.   van den Hoogen, L. L. *et al.* Serology describes a profile of declining malaria transmission in

Farafenni, The Gambia. *Malar. J.* **14**, 416 (2015).

22.   Akpogheneta, O. J. *et al.* Duration of Naturally Acquired Antibody Responses to Blood-Stage

Plasmodium falciparum Is Age Dependent and Antigen Specific. *Infect. Immun.* **76**, 1748–1755

(2008).

23.   White, M. T. *et al.* Dynamics of the Antibody Response to Plasmodium falciparum Infection in

African Children. *J. Infect. Dis.* **210**, 1115–1122 (2014).

24.   Crompton, P. D. *et al.* A prospective analysis of the Ab response to Plasmodium falciparum

before and after a malaria season by protein microarray. *Proc. Natl. Acad. Sci. U. S. A.* **107**,

6958–63 (2010).

Table 1. Sero-prevalence in children aged 1-15 years by antigen, geographical region, and transmission season. Mean estimate of sero-prevalence is

shown as percentage, with 95% confidence interval shown in parentheses.

	PfMSP1$_{19}$	PfAMA1	Etramp5.Ag1	Rh2.2030	EBA175	GEXP18	HSP40.Ag1
West Coast Region							
July 2013 (n=314)	3.5% (1.5 - 5.5)	7.0% (4.2 - 9.8)	6.1% (3.4 - 8.7)	1.4% (0.0 - 3.1)	1.9% (0.1 - 3.8)	12.6% (8.0 − 17.1)	6.3% (3.0 - 9.6)
Dec 2013 (n=317)	8.2% (5.1 − 11.2)	6.9% (4.1 − 9.7)	13.6% (9.8 − 17.3)	3.5% (1.5 − 5.5)	1.9% (0.4 − 3.4)	16.4% (12.3 − 20.5)	7.9% (4.9 − 10.9)
Upper River Region							
July 2013 (n=437)	5.9% (3.7 − 8.2)	25.6% (21.5 − 29.7)	9.8% (7.0 − 12.6)	12.1% (9.1 − 15.2)	9.6% (6.8 − 12.4)	28.8% (24.6 − 33.1)	13.0% (9.9 − 16.2)
Dec 2013 (n=390)	20.8% (16.7 − 24.8)	36.7% (31.9 − 41.4)	30.3% (25.7 − 34.8)	27.9% (23.5 − 32.4)	17.4% (13.7 − 21.2)	36.7% (31.9 − 41.4)	23.8% (19.6 − 28.2)
Apr 2014 (n=504)	14.7% (11.6 − 17.8)	31.7% (27.7 − 35.8)	23.8% (20.1 − 27.5)	23.6% (19.9 − 27.3)	15.5% (12.3 − 18.6)	35.1% (31.0 − 39.3)	24.4% (20.7 − 28.2)
Dec 2014 (n=449)	16.0% (12.6 − 19.4)	31.0% (26.7 − 35.2)	26.9% (22.8 − 31.1)	22.9% (19.1 − 26.8)	14.9% (11.6 − 18.2)	43.9% (39.3 − 48.5)	28.3% (241. − 32.5)

Figure 1. *Pf*MSP1.19 **sero-conversion rates by transmission season and geographical region.** Mean
and 95% confidence intervals of sero-prevalence for each age group are shown as circles and vertical
lines, respectively. Mean fit of the reverse catalytic model is shown as a solid line for the end of the
transmission season (December) and dotted line for the dry season (April) or start of the
transmission season (July). Shaded regions are the 95% confidence interval of the model fit

Figure 2. *Pf*AMA1 **sero-conversion rates by transmission season and geographical region.** Mean
and 95% confidence intervals of sero-prevalence for each age group are shown as circles and vertical
lines, respectively. Mean fit of the reverse catalytic model is shown as a solid line for the end of the
transmission season (December) and dotted line for the dry season (April) or start of the
transmission season (July). Shaded regions are the 95% confidence interval of the model fit

Figure 3. Age-dependent antibody acquisition for Etramp5.Ag1 by geographical region and
transmission season. Mean and 95% confidence intervals of geometric mean antibody levels for
each age group are shown as circles and vertical lines, respectively. Median fit of the antibody
acquisition model is shown as a solid line for the end of the transmission season (December) and
dotted line for the dry season (April) or start of the transmission season (July). Shaded regions are
the 95% credible intervals of the model fit.

Figure 4. Age-dependent antibody acquisition for GEXP18 by geographical region and transmission
season. Mean and 95% confidence intervals of geometric mean antibody levels for each age group
are shown as circles and vertical lines, respectively. Median fit of the antibody acquisition model is
shown as a solid line for the end of the transmission season (December) and dotted line for the dry
season (April) or start of the transmission season (July). Shaded regions are the 95% credible
intervals of the model fit.

Figure 5. Age-dependent antibody acquisition for HSP40.Ag1 by geographical region and transmission season. Mean and 95% confidence intervals of geometric mean antibody levels for each age group are shown as circles and vertical lines, respectively. Median fit of the antibody acquisition model is shown as a solid line for the end of the transmission season (December) and dotted line for the dry season (April) or start of the transmission season (July). Shaded regions are the 95% credible intervals of the model fit.

Figure 6. Association of pre-MDA dry season antibody levels and odds of clinical malaria (a) or asymptomatic infection (b) during transmission season post-MDA. Odds ratios are adjusted for age, LLIN use and MDA compliancy. Clinical malaria is defined as clinical or RDT confirmed case, asymptomatic infection is defined as PCR-positive and clinically or RDT-negative.

504